Tracking every rollback, reversal, and overreach — and the path back to the America we know.
The Trump administration announced 100% tariffs on patented drugs to force pharmaceutical companies into pricing negotiations and shift manufacturing to America. This action leverages tariff threats to compel drugmakers into 'most-favored nation' pricing deals. The policy directly impacts drug prices and availability for American consumers while pressuring companies to relocate production domestically.
Executive Order 14336 directs the establishment and filling of a Strategic Active Pharmaceutical Ingredients Reserve to strengthen domestic pharmaceutical supply chains. The order aims to reduce U.S. dependence on foreign sources for critical drug components and improve resilience against supply disruptions. Americans may see increased availability and potentially lower costs for essential medications through enhanced domestic pharmaceutical production capacity.
President Trump signed Executive Order 14297 to implement Most-Favored-Nation (MFN) pricing for prescription drugs, requiring Medicare to pay no more than the lowest price paid in other developed nations. The order aims to reduce drug costs for American patients and Medicare spending by allowing the government to negotiate lower pharmaceutical prices based on international benchmarks.
Executive Order 14293 signed on May 5, 2025, removes regulatory barriers to increase domestic production of critical medicines in the United States. The order streamlines FDA approval processes and reduces compliance requirements for pharmaceutical manufacturers. This aims to reduce American dependence on foreign drug sources and lower medication costs for consumers.
President Trump signed Executive Order 14273 on April 15, 2025, implementing measures aimed at lowering prescription drug prices for American consumers. The order directs federal agencies to reduce pharmaceutical costs through regulatory reform and market mechanisms. This action is intended to decrease out-of-pocket medication expenses for Medicare, Medicaid, and privately insured Americans.
On March 3, 2025, President Trump signed Executive Order 14228, further amending duties addressing the synthetic opioid supply chain originating from China. The order modifies existing tariff or enforcement mechanisms related to Chinese opioid precursors and related materials. Confirmed direct impacts on Americans include altered costs for pharmaceutical inputs and potential effects on opioid treatment medication availability and pricing.
President Trump signed Executive Order 14200 on February 5, 2025, amending duties addressing the synthetic opioid supply chain from the People's Republic of China. The order modifies tariff and trade policies targeting Chinese opioid precursors and finished products. This directly impacts American pharmaceutical supply chains, drug prices, and law enforcement efforts against fentanyl trafficking.
Executive Order 14200 was signed on February 5, 2025, amending duties and enforcement mechanisms related to synthetic opioid supply chains from China. The order modifies existing tariff and import protocols for substances and precursors identified as contributors to opioid trafficking. The confirmed direct impact includes changes to customs enforcement procedures and potential alterations to import costs for pharmaceutical and chemical manufacturers sourcing from China.
Executive Order 14195 was signed on February 1, 2025, directing the imposition of duties on synthetic opioids and precursor chemicals sourced from China. The order establishes tariffs and trade restrictions on these substances to disrupt supply chains. The confirmed direct impact includes increased costs for pharmaceutical manufacturers and potential effects on opioid medication availability and pricing for Americans.
On May 16, 2019, President Trump signed Proclamation 9761 removing India from the list of beneficiary developing countries under the Generalized System of Preferences (GSP) program established by the Trade Act of 1974. The proclamation eliminated India's duty-free access to U.S. markets for approximately 2,000 product categories, effective June 5, 2019. Indian exporters faced tariffs on products previously entering the U.S. duty-free, affecting American importers and consumers of goods including pharmaceuticals, chemicals, and textiles.